Strategic collaborations There are active and high-profile partnerships with Biocartis, MindPeak, and PathAI, signaling openness to joint development of precision oncology solutions, AI-enabled pathology, and integrated biomarker workflows that can expand joint sales opportunities.

Expanded genomic offerings Launch of Luminos Comprehensive a 164-gene CGP panel and IVDR-compliant in-house testing suggests a strong capability to upsell advanced genomic profiling services to oncology programs and translational research projects.

Legacy and accessibility The Discovery Legacy Program provides discounted access to curated, well-characterized older biospecimens, creating a gateway for academic and biotech customers to source readily usable materials at scale, potentially increasing order volume.

Integrated biospecimen platform One-stop access to large-scale, well-characterized biospecimens and biomarker data across hundreds of studies, reduces vendor fragmentation for customers and enables cross-sell of multi-omic services and therapeutic program support.

Global capacity and speed A robust platform optimized for speed and scale, including GMP and RUO materials, positions the company to win larger, faster-moving cell and gene therapy and precision medicine programs, especially where timelines and data reliability matter.